Loughborough University The Centre for Biological Engineering

Acquisition and Receipt of Biological Materials

Doc Ref: FS008.1 : HTA-PR-FORM/007

Version N°:

1.0

Issue Date:

ARF No: CBE/ARF/0005

PART A: To be completed by the Receiver (a separate form must be completed for each sample type)									
A1. Details of Sample/Specimen									
Type/ID: (eg primary cell, cell line, tissufluid, excreta, biological agent)	ite, body	Human Cord Blood (Ficollect) Coset iso 3x 50pl type containing 2 face ficall Cord Blood							
Format / Quantity: (eg vials, slides, e	etc) 3× 50	3x 50ml the containing 2/me ficall							
Tissue site/Organ source:	Cont	Cord Blood							
Batch N°:									
Is the sample/specimen considered to be Relevant Material under the Human Tissue Act (HTA)? If No, go to section A2.									
Is the material obtained from an HTA licenced Tissue Bank with REC approval for generic research use?									
Is the material obtained for storage and use under a project specific NHS REC approval?									
Is the material licensable under the HTA? Indicate source below:						☑Yes □No			
☑HTA licensed organisation ☑Commercial Supplier □ Imported (from outside England, Wales or N.Ireland)									
If Yes, list lot numbers (or other identifier) & the corresponding assigned unique sample ID	677	6221221192 367 108			nique ID (Procuro):				
If Yes, provide Project Ref N°:	BRAD60	BRADGO & BRADIO							
If Yes, provide the name of the PI: Pof Not Thomas									
A2. Details of Receipt									
Date/Time of receipt	Date	13/05/21		Time:	17:00				
ID of Receiver	Name:	JON HARRIMAN		Dept:	CBE				
ID of Supplier/Provider	Name:	JON HARRIMAN Anthony Nolon		Country:	U.K.				
PART B: To be completed by the	Receiver								
B1. Inspection and Quarantine									
Has a biological risk assessment for the use of this material been approved?		☑Yes □No	Ref Number: BRA060, BRA010						
Physical integrity of the material(s) acceptable?		ØŸes □No	If No, describ	cribe action taken					
Quantity received correct?		⊠Ýes □No	If No, describe action taken						
Labelling correct and legible?		ØÝes □No	If No, describe action taken						
Is the relevant documentation attached to this form?	C of A or equivalent quality	evidence of	∕ZÍYes □No □N/A						
		Agreements to enable transfer of		□N/A	φ				
If No, add reference or details to ensure traceability	Details/evidence/assurance of		✓Yes □No	□N/A	a t	· *			

7. The second of	Other (describe) □Yes □No □N/A						
	Building/Room CBE HJO		n e e e e e e e e e e e e e e e e e e e					
Temporary storageQuarantine location (as applicable)	Storage Unit ID		B7 R5 BOX C Mx 19-25					
	Within storage unit location ID							
	Date/Time of quarantine		17/05/21					
Submitted by:	Signature: Date: 13/05/2.		17/05/21 Date: 13/05/21					
PART C: To be completed by the departmental Quality Manager								
C1. Quality Assurance Checks								
Has the sample/specimen been s	☐Yes ☐No ☐N/A							
Has the donor been screened for	□Yes □No □N/A							
Has the sample/specimen been s	□Yes □No □N/A							
Is there evidence that the supplied or other recognised certification?	□Yes □No □N/A							
For HTA licensable material, is the and use of the material under the	□Yes □No □N/A							
Is there sufficient evidence to sup	□Yes □No □N/A							
C2. Approval for release from quarantine								
Can the material be released from quarantine and transferred to designated storage area or released for processing?								
		☐Accept as is, bu	t with extra controls	18 g				
If No, provide recommendations for deposition of the material and the results of any action relating to non-conforming material.		☐Rework or reprospecified requirem						
		☐Test to meet sp	ecified requirements					
		☐Return to suppl	ier/provider					
	□Disposal							
If Yes, provide details of storage applicable)		Building/Room		A				
		Storage Unit ID		above				
	ocation (as	Within storage un	it location ID	α3				
		Database Referen	ce					
		Date/Time of tran	sfer					
Approved by:		Signature:		Date:				